Tag

Patent

A Wake Up Call about Obviousness-type Double Patenting – the Effect of In re Cellect

What many seem to have understood from Gilead Sciences, Inc. v. Natco Pharma Limited (Fed. Cir. 2014), has been clearly set forth in the recent...

Written Description: Are We Headed for a New Era of Heightened Messier Requirements?

At least pharmaceutical patents in the US may be headed for more stringent application of written description requirements as well as a more confusing unfocused...

Ryan Pool to Speak to the JPAA

Ryan Pool has been asked by the AIPLA IPPJ to speak to the Japan Patent Attorneys Association on the topic of holding interviews with US...

MWZB tackles Patent Strategies for Blockchain, Cryptocurrencies, and NFTs

On April 27, Allison Gaul (www.mwzb.com/personnel/allison-gaul) and William Nixon (www.mwzb.com/personnel/william-nixon ) of the Electrical, Computer, and Software Group lead Japanese patent professionals in a discussion...

MWZB Posted on IPTouring.com

MWZB is proud to announce that Ryan Pool’s article entitled, “The Inherency Doctrine and How You Can Use it to Obtain Patents” was published on...

Value in Underutilized Design Patents

Design patent protection is distinct from utility patent protection. Design patents protect the ornamental features of an article of manufacture rather than its utilitarian features....

Diagnostic Peptide Panels Patent-Ineligible?

Oxford Immunotec Ltd. v. Qiagen, Inc. et al., pending in the U.S. District Court, D. Mass. (Case 1:15-cv-13124-NMG), likely has a long way to go before...

Update: From USPTO Patent Eligibility Guidelines

This is an update from our newsletter of January 2015. On July 30, 2015, the USPTO issued an update regarding the 2014 Interim Guidance on...

USPTO Introduces Expedited Patent Appeal Pilot

The USPTO is providing a temporary basis under which an appellant may have an ex parte appeal to the Patent Trial and Appeal Board (Board)...
1 2 3

Categories

MWZB Newsletter Signup

Subscribe